Judge Du would have easily said that Cochicine effectiveness in gout was obvious. Let the generics file an ANDA and market their generics. FDA said NO. Take the generics off the market and honor the use patent.
I still don't understand why people think 7% of Vascepa Rx's are for high trig no medical benefit claim. No doctor will be writing for Vascepa hoping it didn't have CVD protection. If a doctor did he needs his license reviewed.
These legal routes are slow. The obviousness will show in how generics price and Insurance requires a use entry. The stock will move on those factors. Amarin will be waiting for damages from low IQ infringement cases to pay damages. Money in the bank so to say for generics dispensed. Too obvious infringement could pay treble damages.
News 
Market Data 
Discover 
AI
